We have covered Pfizer’s antitrust suit against Johnson & Johnson, the manufacturer of REMICADE (infliximab), as well as a related antitrust litigation filed by retailers Walgreen and Kroger Co. and direct and indirect purchasers of Remicade. The cases generally allege that Johnson & Johnson excluded Pfizer’s infliximab biosimilar from the market through anticompetitive bundling and rebate penalties for insurers and providers, causing inflated prices. The FTC is now also investigating J&J’s contracting practices with respect to REMICADE. In a recent SEC filing, J&J reported: “In June 2019, the United States Federal Trade Commission (‘FTC’) issued a Civil Investigative Demand to Johnson & Johnson in connection with its investigation of whether Janssen’s REMICADE contracting practices violate federal antitrust laws.”
Stay tuned to Big Molecule Watch for further updates.
The post FTC Issues Civil Investigative Demand to Johnson & Johnson Regarding Remicade appeared first on Big Molecule Watch.